Preparation and characterization of curdlan-chitosan conjugate nanoparticles as mucosal adjuvants for intranasal influenza H1N1 subunit vaccine.

Intranasal vaccination offers crucial protection against influenza virus pandemics. However, antigens, especially subunit antigens, often fail to induce effective immune responses without the help of immune adjuvants. Our research has demonstrated that a polyelectrolyte complex, composed of curdlan sulfate/ O -(2-hydroxyl) propyl-3-trimethyl ammonium chitosan chloride (CS/ O -HTCC), effectively triggers both mucosal and systemic immune responses when administrated intranasal. In this study, stable nanoparticles formed by curdlan- O -HTCC conjugate (C O NP) were prepared and characterized. Furthermore, the efficacy of C O NP was evaluated as a mucosal adjuvant in an intranasal influenza H1N1 subunit vaccine. The results revealed that C O NP exhibits uniform and spherical morphology, with a size of 190.53 ± 4.22 nm, and notably, it remains stable in PBS at 4 °C for up to 6 weeks. Biological evaluation demonstrated that C O NP stimulates the activation of antigen-presenting cells (APCs), including macrophages and dendritic cells (DCs), both in vitro and in vivo. Furthermore, intranasal administration of C O NP effectively elicits cellular and humoral immune responses, notably enhancing mucosal immunity. Thus, C O NP emerges as a promising mucosal adjuvant for influenza subunit vaccines. • Curdlan- O -HTCC conjugate nanoparticle (C O NP) was prepared and characterized. • C O NP was spherical, uniform in size and stable in PBS at 4 °C up to 6 weeks. • C O NP significantly stimulated the activation of antigen presenting cells in vitro. • C O NP induced systemic and mucosal immune responses after intranasal administration. [ABSTRACT FROM AUTHOR]